Company intelligence / Profile preview
TORL BioTherapeutics
Culver City, California, USAtorlbio.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 2
01
Overview
TORL-1-23 (lead candidate) has demonstrated clinically meaningful, durable and confirmed responses with a generally manageable safety profile in patients with Claudin 6 Positive (CLDN6+) cancers. Phase 1 data supports initiation of a registration-enabling Phase 2 study in patients with CLDN6+ Platinum-Resistant Ovarian Cancer[7].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Strategic partnership with the Slamon Research Lab at UCLA
Beyond the preview
Go deeper on TORL BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TORL BioTherapeutics.